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M A J O R A R T I C L E
Postnatal Human Herpesvirus 8 and Human
Immunodeficiency Virus Type 1 Infection
in Mothers and Infants from Zambia
Brad P. Brayfield,1 Saul Phiri,1,4 Chipepo Kankasa,4 Jubra Muyanga,4 Hamakwa Mantina,4 Geoffrey Kwenda,1,4
John T. West,1 Ganapati Bhat,4 Dave B. Marx,2 Winslow Klaskala,1 Charles D. Mitchell,3 and Charles Wood1
1Nebraska Center for Virology, School of Biological Sciences, and 2Department of Biometry, University of Nebraska, Lincoln; 3University of Miami
School of Medicine, Miami, Florida; 4University Teaching Hospital, Lusaka, Zambia
The specific route and timing of human herpesvirus (HHV) 8 infection in regions where Kaposi sarcoma is
endemic are not known. HHV-8 infection and any risk factors that may be associated with HHV-8, including
human immunodeficiency virus (HIV) type 1 infection, were monitored during the 12-month postdelivery
period for 416 mothers and 485 infants from Lusaka, Zambia. HHV-8 incident infection rates during this
period were 3.2 and 5.3 infections/100 person-years for infants and mothers, respectively. HHV-8 infection
among infants was not associated with HHV-8 or HIV-1 infection in the mother. Among the HHV-8–positive
infants, 2 of 12 tested were found to have HHV-8 DNA in their peripheral blood mononuclear cells at birth,
which suggests that in utero infection is possible. However, most HHV-8–positive infants appeared to have
acquired infection either intrapartum or postpartum. The present study indicates that transmission of HHV-
8 to infants can occur early and is likely via multiple routes.
Human herpesvirus (HHV) 8, or Kaposi sarcoma (KS)–
associated herpesvirus, a gamma herpesvirus first iden-
tified in 1994 in biopsy tissue from a patient with AIDS
and KS [1], is now thought to play a critical role in
the development of KS, as well as other lymphoprolifer-
ative diseases, such as primary effusion lymphoma and
multicentric Castleman disease [2]. Four epidemiolog-
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ical forms of KS have been recognized: classic, endemic,
iatrogenic, and AIDS associated [3]. The number of re-
ported cases of KS varies according to geographic regions
and the specific type of KS. Before the early 1980s, KS
was rare in Europe and the United States but was prom-
inent in regions of equatorial Africa. This formof African
KS, known as “endemic KS,” is an aggressive disease that
usually involves multiple regions of the body, such as the
lymph nodes and the extremities. In addition, endemic
KS presents between the ages of 25–40 years, in contrast
to classic KS, which is largely observed in elderly men
of Mediterranean or Jewish descent. Since the early
1980s, as human immunodeficiency virus (HIV) type 1
infection has increased, AIDS-associated KS has become
prominent in several regions of the world, including Af-
rica. This form of KS is more aggressive than endemic
KS and is often multifocal, involving the lymph nodes,
visceral organs, and other mucosal surfaces. AIDS-as-
sociated KS is predominantly found in heterosexual
adults and children in parts of Africa but is most prev-
alent among HIV-1–positive homosexual men in the
Western world [3].
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The number of reported cases of childhood KS has increased
dramatically in several countries in sub-Saharan Africa since
the onset of the AIDS epidemic [4, 5]. This contrasts with
reports in the United States and northern Europe, where KS
is rarely seen in children [3]. In Zambia, the number of reported
cases of childhood KS has increased significantly since the onset
of the AIDS epidemic, accounting for 0%–2% of childhood
malignancies in the early 1980s and 20%–25% of childhood
malignancies by 1992 [5–8]. HHV-8 seroprevalence follows a
similar pattern, with high seroprevalence in the general pop-
ulation observed in regions of high KS incidence, such as Italy,
sub-Saharan Africa, and regions of South America. Several
cross-sectionally designed studies of HHV-8 seroprevalence in
several age groups from regions of Africa where KS is endemic
suggest that primary infection with HHV-8 occurs during child-
hood, with increasing seroprevalence observed through puberty
[9–16]. In Zambia, an HHV-8 seroprevalence rate near 50%
has been reported among adolescents and childbearingwomen,
and the seroprevalence rate increases with age [17, 18]. Viral
DNA has also been detected in biopsy tissue and peripheral
blood mononuclear cells (PBMC) of infants and children with
febrile illnesses in Zambia, further supporting the concept that
HHV-8 infection occurs early in life in Africa [9, 14]. Similar
studies conducted in the United States have shown that primary
infection likely occurs in adults, with low seroprevalence ob-
served in children [19].
In contrast to what is known about HHV-8 seroprevalence,
information concerning the route of transmission and any risk
factors that may influence transmission is still limited. Trans-
mission of HHV-8 has been strongly linked to homosexual
contact in North America and western Europe. HHV-8 sero-
positivity has been reported to be correlated with receptive oral
sex, the number of sex partners, and the use of amyl nitrate
[20–24]. In addition, a study of patients from public health
clinics reported a higher seroprevalence among commercial sex
workers than non–commercial sex workers [25]. The absence
of antibodies and viral DNA in children and a high seroprev-
alence among children in an isolated region of southern Texas
indicate that nonsexual transmission is not a significant route
of infection in the United States [19, 26]. In some parts of
South America and Africa and in regions where low socio-
economic conditions exist, a higher proportion of the general
population is infected with HHV-8 than in the United States
[10, 12, 14, 16, 26, 27]. In these studies, children were shown
to have a high seroprevalence of HHV-8, ranging from 13% to
48% among children aged 2–15 years [10, 14]. One study also
indicated significant familial correlations in HHV-8 seroprev-
alence between mother and child and among siblings [16].
Furthermore, a recent study identified matching sequences of
the variable K1 gene in saliva collected from various family
members and an index case patient with KS [28]. These studies
strongly suggest that nonsexual means of infection, possibly
intrafamilial transmission via saliva or other close contact, may
be a significant source of infection in some regions.
Although cross-sectional studies have established the sero-
prevalence of HHV-8 in children from regions where KS is
endemic, several questions about HHV-8 infection still need to
be addressed. The incidence of HHV-8 infection among chil-
dren, the specific routes of transmission in regions where KS
is endemic, the role of HIV-1 and socioeconomic and behav-
ioral factors in the transmission of HHV-8 to children, and the
impact other diseases have on HHV-8 transmission have not
been fully examined. To address some of these questions, a
large study was initiated with the University Teaching Hospital
(UTH) in Lusaka, Zambia, to study both HHV-8 and HIV-1
infections in a population of childbearing women and their
infants. The present study examined HHV-8 and HIV-1 infec-
tions in infants and mothers in an effort to increase under-
standing of the increasing incidence of KS among young chil-
dren in Zambia. More important, this study aimed to increase
understanding of the pathogenesis of KS, which will be useful
in identifying potential treatments and/or preventative mea-
sures to decrease the incidence of KS. Here, we report a pro-
spective study of the incidence of HHV-8 and HIV-1 infection
among infants during the first 12 months after delivery and
the risk factors associated with HHV-8 infection in a group of
mothers and infants from a region where HHV-8 is endemic.
SUBJECTS AND METHODS
Patient population. Study participants were part of an on-
going cohort study of HHV-8 transmission at the UTH in
Lusaka, Zambia. In this cohort, healthy childbearing women
were screened for HHV-8 and HIV-1 after admission to the
labor ward of UTH. Before giving birth, the women were coun-
seled and informed about HIV-1, HHV-8, and the ongoing
study; then written consent to participate was obtained.Women
who were in active labor were excluded, and only the first infant
from multiple births was included. In the present study, a group
of 416 mothers and 485 infants who returned for follow-up
analysis after delivery and with an available blood sample taken
12 months after delivery were tested for infection with HHV-
8 and HIV-1 at 12 months after delivery, with primary focus
on HHV-8 incident infection and attention to HIV-1 only as
a correlate to HHV-8 infection.
Sample collection and serological testing for HHV-8 and
HIV-1. Blood was collected from mothers before delivery
and from infants within 24 h of delivery, by venipuncture into
acid citrate dextrose tubes, and was processed as described else-
where [29]. In brief, whole blood was separated into plasma
and cell fractions by centrifugation, and PBMC were isolated
from the cell fraction using lymphocyte separation media (In-
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vitrogen), according to the manufacturer’s instructions. An ali-
quot of the plasma and the PBMC was then stored at 80C
for future use. Lytic and latent antibodies to HHV-8 were de-
tected using a monoclonal antibody–enhanced immunofluo-
rescence assay (mIFA) with minor modifications, as described
elsewhere [29, 30]. For the lytic mIFA, BC-3 cells [31] (provided
by Dr. Ethel Cesarman, Weill Medical College, Cornell Uni-
versity, New York, NY), a primary effusion lymphoma-derived
cell line that harbors HHV-8 and is free of Epstein-Barr virus
(EBV), were induced into lytic replication by addition of TPA
to the culture medium at a final concentration of 20 ng/mL
for 72 h. The cells were washed with PBS and spotted onto
slides, air dried, and fixed in cold acetone at 20C. Prior to
serological testing, an aliquot of each test sample was heat
inactivated at 56C for 45 min and used for subsequent sero-
logical analysis. Each test sample was assayed at a dilution of
1:40 and was examined by fluorescence microscopy. For the
latent mIFA, BC-3 cells not induced with TPA were spotted
onto slides and assayed as above. Test samples that exhibited
punctate nuclear staining were considered to be positive for
HHV-8. To exclude background fluorescence, all positive serum
samples were tested as above, using BJAB cells, an HHV-8–
and EBV-negative B cell lymphoma cell line [32]. For plasma
to be considered positive for HHV-8, concordant positive re-
sults from 2 independent mIFA tests and a negative result from
the BJAB mIFA had to be achieved. For lytic antibody titer
determination, serial 2-fold dilutions of the test serum were
performed, and each dilution was assayed using mIFA. The
inverse of the last dilution that tested positive was considered
to be the end-point titer. Test plasma that was positive by mIFA
was further tested using an ELISA made from a solubilized
HHV-8 whole-virus extract (Advanced Biotechnologies). The
ELISA was used according to the manufacturer’s instructions
with a test serum dilution of 1:40.
Serological testing for HIV-1 was performed as described
elsewhere [29]. Plasma was screened for HIV-1 antibodies using
Capillus (Trinity Biotech) and Determine (Abbott Laboratories)
rapid assays, according to the manufacturers’ instructions, and
by IFA. Positive test samples were then analyzed by Western
blot, using recombinant HIV-1 clade C p24 and gp160 (pro-
vided by Drs. Daniel Perez-Filgueira [Department of Biotech-
nology, INIA, Madrid] and Shiu-Lok Hu [University of Wash-
ington, Seattle], respectively). The reactive bands were detected
using nitro blue tetrazolium and 5-bromo-4-chloro-3-indoly-
phosphate colorimetric substrates, according to the manufac-
turer’s instructions (Roche Laboratories).
DNA extraction, polymerase chain reaction (PCR), and
Southern blot analysis. DNA was extracted using phenol-
chloroform-isoamyl alcohol (PCA) and proteinase K, according
to standard methods, or by Puregene DNA Purification System
(Gentra Systems), according to the manufacturer’s instructions.
In brief, PBMC pellets were resuspended in standard cell lysis
solution or Gentra Systems cell lysis solution and incubated
overnight. For PCA extraction, 2 rounds of PCA and 1 chlo-
roform-isoamyl alcohol extraction were performed on all sam-
ples. This was followed by ethanol precipitation at 20C. For
Gentra Systems lysis, cell pellets were extracted according to
manufacturer’s procedure and resuspended in Tris-EDTA. PCR
for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
performed on all extracted samples, and PCR-positive samples
were then used for HHV-8 PCR. HHV-8 PCR was performed
using primers specific for 3 genes—ORF26, gB, and K1—as
described elsewhere [29]. Screening of DNA samples was per-
formed initially with ORF26 primers and 400 ng of genomic
DNA. For confirmation of ORF26-positive DNA samples,
primers specific for gB and K1 were used on those samples
initially found to be ORF26 positive. Southern blot of all PCR
products was performed for confirmation using digoxygenin-
labeled probes specific for these genes, according to the man-
ufacturer’s protocols (Roche Laboratories).
Risk factor analysis for HHV-8 and HIV-1 infection. All
statistical analysis was carried out using SAS software (version
8; SAS Institute). Odds ratios (ORs), 95% confidence intervals
(CIs), and P values were generated for each risk factor, and
factors with and CIs not containing 1 were consideredP ! .05
to be significant. Information regarding sociodemographic
characteristics, behavior, and prior exposure status to sexually
transmitted diseases (STDs) were obtained by an attending phy-
sician using standardized questionnaires at the time of recruit-
ment into the study and at each subsequent visit to the follow-
up clinic, as described elsewhere [29].
RESULTS
Follow-up cohort for HHV-8 and HIV-1 incident infection.
To analyze our population for infection during the 12-month
postdelivery period, we first analyzed the seroprevalence of
HHV-8 and HIV-1 at the time of delivery. From an ongoing
cohort at UTH, 3150 healthy women had been screened pre-
viously for HHV-8 and HIV-1 at the time of delivery at UTH.
At the time of sample testing, mIFA was performed because it
was determined to be the most specific and sensitive assay for
analyzing HHV-8 seroprevalence. Using the mIFA, a high se-
roprevalence of both HHV-8 and HIV-1 was observed in this
population (table 1). Women from this cohort showed a se-
roprevalence of 40% ( ) and 30% ( ) for1256/3150 957/3150
HHV-8 and HIV-1, respectively. Women who were HIV-1 pos-
itive were more likely to be HHV-8 positive than those who
were HIV-1 negative (OR, 1.42; 95% CI, 1.22–1.66), thus in-
dicating a possible association between HIV-1 and HHV-8 in-
fection. The mothers and infants were divided into 4 groups
on the basis of maternal serostatus for HHV-8 and HIV-1 at
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Table 1. Human herpesvirus (HHV) 8 and hu-
man immunodeficiency virus (HIV) type 1 sero-
prevalence in a population of women who gave
birth at the University Teaching Hospital, Lusaka,
Zambia.
HHV-8
serostatus
HIV-1 serostatus
TotalPositive Negative
Positive 438a 818 1256 (40)
Negative 519 1375 1894
Total 957 (30) 2193 3150
NOTE. Data are no. (%) of women.
a HIV-1–seropositive mothers were significantly more
likely to be HHV-8 seropositive than were HIV-1–seroneg-
ative mothers (odds ratio, 1.42; 95% confidence interval,
1.22–1.66).
Table 2. Sociodemographic characteristics of 485
mother-infant pairs, by results of human herpesvirus (HHV)
8 serological analysis.
Characteristic
HHV-8
mothers
(n p 236)
HHV-8
mothers
(n p 249)
Age, mean years (range) 24.9 (14–41) 24.9 (14–43)
Household size, mean no.
of members (range) 4.8 (1–14) 5.0 (1–17)
Household income
1$75.00/month 15 18
$75.00/month 199 204
NA 22 27
Marital status
Single 15 20
Married 214 221
Othera 7 8
Duration of education, years
7 140 128
17 96 121
Tribe
Bemba 62 78
Nyanja 122 112
Other 52 59
Employment status
Employed 30 55
Unemployed 206 194
Sex of infant
Female 119 116
Male 117 133
No. of infants breast-fed/
total no. of infants (%) 232/236 (98) 248/249 (99)
NOTE. Data are no. of mothers, except where noted. NA, not
available.
a Includes divorced, widowed, and cohabiting mothers.
the time of delivery: group 1 included mothers who were se-
ropositive for both viruses, group 2 included mothers who were
HHV-8 positive and HIV-1 negative, group 3 included mothers
who were HIV-1 positive and HHV-8 negative, and group 4
included mothers who were negative for both viruses. Of the
screened population of 3150 mother-infant pairs (MIPs), 1431
returned to UTH for at least one follow-up visit and were
recruited for longitudinal follow-up; 740 of these were still
available for follow-up (“active”) at the time of analysis. The
rest of the screenedMIPs were considered to be inactive because
they did not return for follow-up analysis; they were untrace-
able, had relocated, or had died before follow-up analysis. Of
the 740 MIPs who were active for follow-up, 485 infants and
416 mothers with available specimens at 12 months after de-
livery were monitored for HHV-8 and HIV-1 infection within
this time period. The sociodemographic characteristics of the
study population are shown in table 2, according to the HHV-
8 serostatus of the mothers of the 485 infants tested. HHV-
8–positive mothers were more likely to be unemployed than
were HHV-8–negative mothers (OR, 0.51; 95% CI, 0.32–0.84).
No other characteristics examined were significantly different
between HHV-8–positive and –negative mothers (table 2). The
number of infants and mothers in the follow-up cohort, the
number of deaths, and the number of patients lost to follow-
up by withdrawal from the study or relocating during the study
period are shown in table 3. A total of 54 infants and 3 mothers
had died by 12 months after delivery, with significantly more
deaths among infants born to HIV-1–positive mothers (groups
1 and 3) than HIV-1–negative mothers (groups 2 and 4) (OR,
10.1; 95% CI, 5.08–20.2). No significant difference in the num-
ber of infant deaths was observed between those born to HHV-
8–positive and –negative mothers (table 3; OR, 1.14; 95% CI,
0.65–1.99). Mothers in group 4 were the least likely to be lost
to follow-up, which reflects the fact that they were dual negative
at the time of delivery and were the most healthy mothers with
the most healthy infants in the study.
HHV-8 infection by 12 months after delivery. For initial
determination of HHV-8 infection, plasma samples taken at 12
months after delivery from both mothers and infants were
analyzed by mIFA, as described elsewhere [29, 30], followed by
an IFA for latent antibodies to HHV-8. The mIFA has been
found to be sensitive in detecting antibodies to HHV-8 and
most practical for testing large numbers of samples, even
though the interpretations of the results could be subjective.
Recently, an HHV-8–specific ELISA was developed and it is
now commercially available [33]; therefore, all IFA-positive
samples were further confirmed by ELISA, and only those pa-
tients who tested positive by both IFA and ELISA were con-
sidered to have seroconverted. Only mothers in groups 3 and
4 who had negative serological test results at delivery were tested
for HHV-8 infection. Mothers who tested negative at the time
of delivery but then tested positive 12 months later were con-
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Table 3. Twelve-month follow-up cohort analyzed for human
herpesvirus (HHV) 8 and human immunodeficiency virus (HIV)
type 1 infection, by maternal serostatus.
Group
(serostatus)
Infants
(np 485)
Mothers
(np 416)
Deathsa
Lost to
follow-upbInfants Mothers
1 (HHV-8/HIV-1) 52 52c 21d 1 8
2 (HHV-8/HIV-1) 184 156 7 0 26
3 (HHV-8/HIV-1) 83 52 22e 2 23
4 (HHV-8/HIV-1) 166 156 4 0 2
NOTE. Data are no. of subjects.
a No. of deaths within 12-month postdelivery period from the active follow-
up cohort.
b No. of patients from active cohort who either withdrew from the study
or relocated to an untraceable location by 12 months after delivery; they were
not tested for HHV-8 infection.
c Mothers not tested for infection; they were positive at delivery but still
were included in cohort.
d A significant increase in the no. of deaths by 12 months after delivery
was observed among infants born to HIV-1–positive mothers (groups 1 and
3) vs. HIV-1–negative mothers (groups 2 and 4) (odds ratio [OR], 10.1; 95%
confidence interval [CI], 5.08–20.2).
e No significant difference in deaths was observed among infants born to
HHV-8–positive mothers (groups 1 and 2) vs. HHV-8–negative mothers
(groups 3 and 4) (OR, 1.14; 95% CI, 0.65–1.99).
sidered to have seroconverted. Infants from all groups were
tested for infection with HHV-8. To exclude the possibility that
maternal antibodies acquired transplacentally and/or through
breast-feeding were producing false positive results in our infant
population at 12 months, the end-point titer for all positive
infant samples was compared with the corresponding sample
taken at delivery or, if available, with a sample taken at a time
point in between. An infant with an end-point antibody titer
at 6 or 12 months after delivery higher than that at delivery
was considered to have decreasing maternal antibodies being
replaced by increasing levels of infant antibodies as a result of
HHV-8 infection. These infants were then considered to be
infected with HHV-8. The end-point titration for all infected
infants is shown in figure 1. Similarly, titers were measured for
mothers who became infected (data not shown).
The incident infection rates of HHV-8 for all mothers and
infants in our study are shown in table 4. The incident infection
rate was calculated for the total infant and mother population
and within each group by dividing the number of IFA- and
ELISA-positive samples by the number of person-years.Overall,
the HHV-8 infection rate for the infant population during the
first 12 months after delivery was 3.2 infections/100 person-
years, with 18 infections/558 person-years . In our study groups,
HHV-8 incident infection rates were 2.9 (2 infections/69.2 per-
son-years) and 4.8 (10 infections/206.6 person-years) infec-
tions/100 person-years for infants in groups 1 and 2, respec-
tively, and 2.7 (3 infections/112 person-years) and 1.8 (3
infections/170.2 person-years) infections/100 person-years for
infants in groups 3 and 4, respectively. No association was
observed between the infection rates among infants born to
HHV-8–positive mothers (groups 1 and 2) and those born to
HHV-8–negative mothers (groups 3 and 4) (OR, 2.09; 95% CI,
0.77–5.66; table 4). Of the 6 infants from groups 3 and 4 who
were infected, only 1 had a mother who seroconverted in the
same time period, although samples for 2 of the mothers were
not available for testing at 12 months after delivery. The in-
fection rate for the mothers was 5.3 infections/100 person-years,
with 4.4 (3 infections/67.5 person-years) and 5.7 (9 infections/
157.8 person-years) infections/100 person-years in groups 3
and 4, respectively. To analyze the role of maternal HIV-1 in-
fection at delivery in HHV-8 infection by 12 months after de-
livery, the number of infections was compared between our
study groups for both infants and mothers. For the infants, the
number born to HHV-8– and HIV-1–positive mothers (group
1) was compared with the number born to HHV-8–positive
mothers only (group 2). No significant difference between
group 1 (2 infections/69.2 person-years) and group 2 (10 in-
fections/206.6 person-years) was observed (OR, 0.59; 95% CI,
0.13–2.74; table 4). In addition, the incident HHV-8 infection
rates among infants born to HIV-1–positive mothers in groups
1 and 3 (2.9 and 2.7, respectively) were similar to those among
infants born to HIV-1–seronegative mothers in groups 2 and
4 (4.8 and 1.8, respectively). This was also true for the mothers
examined. The incident HHV-8 infection rate by 12 months
after delivery was not significantly different for group 3 HIV-
1–positive mothers (4.4) and group 4 HIV-1–negative mothers
(5.7) (OR, 0.77; 95% CI, 0.20–2.93).
Antibody profile of infants who seroconverted to HHV-8
positive. After examining the infant population for HHV-8
infection, we next wanted to determine the patterns of anti-
bodies to HHV-8 over the 12-month postdelivery period and
to examine whether these patterns indicated a specific route of
transmission. The end-point titer at 0 (delivery), 6, and 12
months after delivery was determined using the mIFA for 14
of the 18 seropositive infants. All infants had at least 2 samples
available for the 12-month postdelivery period, but 4 infants
did not have a baseline sample available for titration, and 6
infants did not have a 6-month sample available. The antibody
titers for the HHV-8–positive infants are shown in figure 1. In
contrast to infants born to HIV-1–positive mothers, infants
born to HHV-8–positive mothers generally had low titers of
passively acquired HHV-8 antibodies at delivery (40–160 or
5–7 log2 U). Three main antibody response patterns emerged.
First, a rapid increase in antibody titer by 6 months after de-
livery, followed by a decrease through month 12, was seen in
infants 1, 7, 9, and 14. Second, a slow increase in antibody titer
throughout the 12 months was seen in infant 10. Third, an
increase in antibody titer from 6 to 12 months after delivery
was seen in infants 2, 4, 8, and 12. Previously, we did not
observe a relationship between the lytic antibody titer of the
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Figure 1. Human herpesvirus (HHV) 8 IgG antibody titer at delivery and at 6 and 12 months after delivery for infants who became HHV-8–positive
by age 12 months. Serial 2-fold dilutions of each test serum sample were tested by monoclonal antibody–enhanced immunofluorescence assay,
beginning with 1:40, as in described in Materials and Methods. The inverse of the last positive dilution was considered to be the end-point titer and
was expressed as a log2 value. Infants with no 6-month sample available for analysis have a single line from delivery to 12 months. Each point
represents an individual patient (patient nos. are given in the key on the right side of each panel). HIV-1, human immunodeficiency virus type 1.
mother and transmission to the infant; therefore, we did not
measure antibody titers of the mothers.
HHV-8 PCR analysis of seroconverting infants from groups
1 and 2. To determine whether mother-to-child transmission
had occurred in utero for the infants who became infected,
HHV-8 PCR was performed on PBMC DNA from all the in-
fected infants of HHV-8–seropositive mothers (groups 1 and
2). Available PBMC from infected infants from both groups
were obtained at the time of delivery, and DNA was extracted.
Of those infants who had control GAPDH-amplifiable DNA, 2
(16%) of 12 were found to be positive for HHV-8 DNA at the
time of delivery and were born to mothers in group 2. In
addition toORF26, the 2 DNA-positive samples were confirmed
with primers specific for gB and K1 genes.
Risk factors for HHV-8 infection during the 12-month post-
delivery period. Statistical analysis was performed to examine
any potential risk factors that may be associated with HHV-8
infection in both infants and mothers and to further investigate
possible transmission routes (table 5). For HHV-8–positive in-
fants, we observed a significant relationship with the mother’s
being employed outside the home (OR, 5.14; 95% CI, 1.98–
13.4) and an inverse association with the mother’s being a
homemaker (OR, 0.17; 95% CI, 0.07–0.46). On the other hand,
all other potential demographic or health-related factors ex-
amined—including infant sex; mother’s history of genital warts,
genital herpes, and syphilis; the presence of skin lesions on the
mother; blood transfusion in the infant; bleeding during labor;
number of mother’s sex partners; positive HIV-1 and/or HHV-
8 serostatus in the mother; household size; and number of
pregnancies—were not significantly related to HHV-8 infection
in the infants. In addition, HIV-1 infection in the infants during
the study period was found to be significantly related to 3
examined risk factors: the mother bleeding during labor, the
presence of new skin rashes or lesions, and swollen lymphnodes
by 12 months after delivery (data not shown). Infection with
HHV-8 among the mothers was not significantly associated
with any of the factors examined, including monthly income,
education, occupation, household size, history of STDs, 11 sex
partner, history of blood transfusion, and the presence of new
skin rashes or lesions by 12 months after delivery (table 5), as
well as age, number of pregnancies, and marital status (data
not shown).
DISCUSSION
The incidence of KS has risen dramatically since the onset of
the AIDS epidemic in Africa, especially among children. The
prevalence of HHV-8, which is now implicated in the patho-
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Table 4. Human herpesvirus (HHV) 8 and human immunodeficiency virus (HIV) type
1 incident infection among infants and mothers within the 12-month postdelivery
period, by maternal serostatus.
Group
(serostatus)
Infants Mothers
HHV-8 HIV-1 HHV-8 HIV-1
1 (HHV-8/HIV-1) 2.9 (2/69.2)a 18.8 (13/69.2) NA NA
2 (HHV-8/HIV-1) 4.8 (10/206.6) 1.9 (4/206.6) NA 2.3 (4/174)
3 (HHV-8/HIV-1) 2.7 (3/112)b 17.6 (20/112) 4.4 (3/67.5)c NA
4 (HHV-8/HIV-1) 1.8 (3/170.2) 0 (0/170.2) 5.7 (9/157.8) 1.9 (3/157.8)
Total 3.2 (18/558) 6.6 (37/558) 5.3 (12/225.3) 2.1 (7/331.8)
NOTE. Data are incident infections/100 person-years (actual infections/person-years). Deaths and
loss to follow-up, including both mothers and infants, were used for person-year data. NA, not applicable
(i.e., participants already were positive at delivery).
a No significant difference in HHV-8 infection between infants born to HHV-8/HIV-1 dually infected
mothers and mothers who were HHV-8 positive only (odds ratio [OR], 0.59; 95% confidence interval
[CI], 0.13–2.74).
b No significant difference in HHV-8 infection between infants born to HHV-8–positive (groups 1 and
2) and HHV-8–negative (groups 3 and 4) mothers (OR, 2.09; 95% CI, 0.77–5.66).
c No significant difference in HHV-8 infection between HIV-1–positive and –negative mothers (OR,
0.77; 95% CI, 0.20–2.93).
genesis of KS, has been shown to be high in adult women and
children in several regions of Africa, including Zambia. Al-
though several studies have indicated that infection with HHV-
8 is likely to occur in childhood, how and when children acquire
HHV-8 is still unclear. Unlike previous reports [9, 10, 12–14,
16], the present study is a longitudinal analysis of HHV-8 and
HIV-1 infection among infants born to infected and uninfected
mothers in a region where HHV-8 is endemic.
Very few studies have examined the incident infection rate
of HHV-8, and the study presented here, to our knowledge, is
the first to document this in an area where HHV-8 is endemic.
Here, we report the incident infection rate of HHV-8 during
the first 12 months of life in a population of MIPs examined
at 12 months after delivery and for MIPs whom a documented
death or loss to follow-up was observed during the study pe-
riod. In our study population, a large number of patients en-
rolled at delivery from an ongoing study in Zambia were lost
to follow-up and, thus, were not examined at 12 months after
delivery. This loss was primarily due to the death of a mother
or infant or because the patient was untraceable after having
relocated. Therefore, interpretation of the observed incident
infection rate is limited to those patients who were still active
at the end of the study, those with documented deaths, or those
who were lost to follow-up and may not be representative of
the entire cohort. In addition, because this is the only study
to examine incident infection in a region where HHV-8 is
endemic, it cannot be compared directly with cross-sectional
studies of seroprevalence. Nevertheless, an HHV-8 infection
rate of 18 of 485 infants is in agreement with several cross-
sectional studies of HHV-8 infection in hospitalized Ugandan
and Italian children !12 months old [12, 13]. However, other
studies using cross-sectional sampling have reported seroprev-
alence rates near 17% in the same age group as our study
population [14]. The high seroprevalence reported could have
been influenced by detection of passively acquired antibodies
from the mother in these infants and/or cross-sectional sam-
pling. The infants in the present study could have acquired
HHV-8 infection either vertically via in utero or intrapartum
routes or horizontally by way of postnatal infection. Postnatal
transmission of HHV-8 could occur via exchange of saliva with
the mother or father or via household contact with family
members, such as siblings. Indeed, several studies have indi-
cated that HHV-8 can be detected in the saliva of HHV-8–pos-
itive individuals [34]. Another possible route of postnatal trans-
mission of HHV-8 from mother to child is via breast milk or
premastication of food; to date, however, there is no direct
evidence demonstrating infectious HHV-8 in breast milk or a
strong association between infection and premastication.
Previous studies have suggested that mother-to-child trans-
mission can occur either vertically or horizontally but that it
is an infrequent event [16, 28, 29, 35]. In addition to serological
analyses from several groups [16, 35, 36], recent detection of
identical sequences of a highly variable region in the K1 gene
of HHV-8 in mother-child pairs from Malawian families that
exhibited a case of KS further supports the notion that mother-
to-child transmission of HHV-8 exists [28]. Furthermore, our
laboratory has recently reported elsewhere [29] the detection
of viral DNA in PBMC at the time of delivery for 2 of 89
infants born to HHV-8–positive mothers, which suggests that
in utero infection occurs but that the incidence may be low.
In contrast, several studies have indicated that vertical trans-
mission of HHV-8 is unlikely to occur. Analysis of 32 HIV-
1–positive mothers and their infants did not find any evidence
of HHV-8 viral DNA or antibodies at 24 months after delivery
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Table 5. Sociodemographic, behavioral, and health-related risk factors by 12 months after delivery asso-
ciated with human herpesvirus 8 infection among infants and mothers.
Risk factor
Infants (n p 485) Mothers (n p 208)
OR 95% CI P OR 95% CI P
Mother employed outside home 5.14 1.98–13.4 .0002 2.62 0.79–8.67 .10
Mother is homemaker 0.17 0.07–0.46 !.0001 0.67 0.19–2.38 .53
Education 7 years 0.80 0.31–2.06 .65 0.70 0.21–2.28 .55
Household size 3 members 1.21 0.47–3.12 .69 1.61 0.5–5.19 .42
Mother HIV-1 0.65 0.15–3.28 .58 1.00 0.26–3.84 1.00
Abnormal deliverya 0.61 0.17–2.19 .45 0.63 0.13–3.07 .57
Bleeding during laborb 2.05 0.25–16.6 .49 3.47 0.37–32.3 .25
Blood transfusion during deliveryc 2.23 0.27–18.1 .44 1.03 1.01–1.06 .55
Maternal lesions or sores 12 months after delivery 1.01 0.99–1.04 .66 1.01 0.99–1.04 .68
Maternal syphilis 0.47 0.06–3.60 .46 0.65 0.08–5.27 .69
Antibioticsd 0.72 0.26–1.96 .51 1.14 0.23–5.63 .87
11 Sex partner in last 3 years 1.12 0.25–5.01 .92 1.15 1.09–1.22 .17
New lesion or rash on infant 12 months after delivery 0.33 0.04–2.53 .26 NA NA NA
Swollen nodes in infant 12 months after delivery 1.02 1.00–1.03 .60 NA NA NA
NOTE. CI, confidence interval; HIV-1, human immunodeficiency virus type 1; NA, not applicable (variable is only associated
with infant); OR, odds ratio.
a Assisted or breach delivery.
b History of bleeding during labor.
c Mother received blood transfusion during delivery.
d Taken by the mother during study period.
[37], whereas serological analysis of 11 infants from HHV-
8–positive mothers revealed no seroconversion by 7 months
after delivery [11]. Given the fact that mother-to-child trans-
mission is likely to occur infrequently, the lack of evidence
supporting mother-to-child transmission in these studies could
be due to the small population size analyzed. In the present
study, several HHV-8–positive infants lacked any antibody titer
at delivery but had high antibody titers at 6 months after de-
livery. This result, combined with the detection of HHV-8 viral
DNA at delivery for 2 seroconverting infants, suggests that
HHV-8 infection occurred perinatally or soon after delivery
and further supports the notion that perinatal and in utero
HHV-8 infection can occur. Furthermore, 1 of the mothers of
the 2 PCR-positive infants was also found to be HHV-8 DNA
positive, whereas all other mothers were PCR negative (data
not shown). Whether perinatal infection is the major route of
HHV-8 transmission in the Zambian population is a current
focus of investigation.
HHV-8 infection in infants during the 12-month post-
delivery study period was associated with the mother’s em-
ployment status and inversely associated with the mother’s be-
ing a homemaker. The significance of this association is not
currently known, but a similar observation was reported in
relation to KS incidence [38]. HHV-8 infection may follow a
pattern similar to that of other infectious agents, in which
transmission is more likely in urban settings where large num-
bers of people are continually interacting with others, compared
with rural settings with limited personal contacts, as suggested
by other researchers [14, 26, 39]. Of interest, we observed no
significant association between HHV-8 and HIV-1 infection in
the infant population studied, nor was there any significant
association between the HIV-1 and HHV-8 status of the moth-
ers. Infants born to mothers who were HIV-1 positive, HHV-
8 positive, or both did not have significantly different HHV-8
infection rates. In fact, the infection rates observed in infants
born to mothers in group 4 (HHV-8– and HIV-1–negative)
were similar to those seen in the other groups, which further
supports the concept that HIV-1 infection in the mothers may
not influence HHV-8 infection in the infants and that mother-
to-child transmission of HHV-8 may be infrequent. In addition,
only 1 HHV-8–positive infant from group 4 had a mother who
also was infected with HHV-8. Our findings indicate that
household contacts could be a source of HHV-8 infection, but
other sources outside of the family may also be involved in
transmission. The relationship between HHV-8 transmission
and household contact is currently being assessed.
Although primary infection with HHV-8 is considered to
occur early in life in regions where HHV-8 is endemic, such
as Zambia, our analysis of HHV-8 infection in previously se-
ronegative mothers revealed an HHV-8 infection rate of 5.3
infections/100 person-years, which indicates that HHV-8 trans-
mission to adults does occur. These results are congruent with
reports from other regions of Africa, where the cross-sectional
seroprevalence of HHV-8 increases with age, suggesting that
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there is continued infection in the adult population [17, 39–41].
Again, because the present study is prospective in design, direct
comparison with other cross-sectional studies is difficult. Nev-
ertheless, the cross-sectional seroprevalence among our moth-
ers at delivery was 40%, which is in agreement with other age-
matched populations in Africa. Sexual transmission of HHV-8
may be the route of infection in this maternal population,
because these mothers were in a sexually active age group.
Alternatively, nonsexual routes of infection via familial contact
with household members, including partners, children, or other
family members, could also be possible. Contact outside the
household with infected persons other than family members
may also be sources of HHV-8 transmission to the women
studied here.
In the present study, no significant association was observed
between HHV-8 infection in the mothers and any of the risk
factors examined, including HIV-1, other STDs, and 11 sex
partner. In addition, similar HHV-8 seroconversion rates were
observed for HIV-1–positive and –negative mothers (groups 3
and 4), which further indicates that HIV-1 infection is not
associated with HHV-8 infection in the mothers. This is con-
sistent with reports from Uganda and French Guiana, which
found no association with several STDs or number of sex part-
ners [16, 41]. The lack of an observed association betweenHIV-
1 infection and HHV-8 seroconversion in the mothers during
the 12-month study period is in contrast to our baseline cross-
sectional screening of mothers delivery at UTH, where HIV-1
was found to be a risk factor for HHV-8 infection. This dis-
crepancy could be due to the short follow-up period of 12
months in which the mothers were examined.
Some limitations in our study exist and should be considered.
Although the socioeconomic characteristics of our study popu-
lation are not significantly different between theHHV-8–positive
and –negative mothers, our study participants were recruited
from themain referral hospital in Zambia, which acceptsmothers
who have complications during pregnancy from the local clinics
throughout Lusaka province. Nevertheless, most of the births in
our study were normal, with few assisted or breach deliveries.
In addition, the 12-month time period used to monitor sero-
conversion is likely to be a small window for analysis of adult
infection. This fact, combined with the limited population size
available for study, could have influenced our observed infection
rates and subsequent risk analysis forHHV-8 andHIV-1 in adults
in this population. Although our initial determination of HHV-
8 infection was based on the mIFA analysis and only those con-
firmed by commercial ELISA were considered to be positive in
the present study, the mIFA showed a higher infection rate in
the infants, but many results could not be confirmed by the
ELISA. Whether this result could be due to the differences in
sensitivity and specificity between the assays and, more impor-
tant, whether the incidence rates reported here are underesti-
mated on the basis of our criteria is currently being investigated.
The present study was the first to document the number of
incident infections of HHV-8 in an area where it is endemic
and examined several risk factors that may be involved in trans-
mission. Evidence was provided indicating that infection with
HHV-8 can occur within the first 12 months of life in an area
where HHV-8 is endemic and that transmission likely occurs
through multiple routes, both vertical and horizontal. Data
from risk factor analysis, PCR, and serum antibody titers also
suggest that in utero transmission occurs but is infrequent and
that postnatal transmission is a more likely route of HHV-8
infection for infants in Zambia.
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